Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Olaratumab with doxorubicin for advanced soft tissue sarcoma. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 Authors' objectives Soft tissue sarcoma is a group of rare cancers that can occur in any part of the body. Sarcoma is usually treated with surgery, but the cancer often returns or spreads to other parts of the body.
Olaratumab is a new drug for the treatment of soft tissue sarcoma that can no longer be treated with surgery. It is delivered directly into the bloodstream through a drip. Some studies have suggested olaratumab may work best in combination with a chemotherapy drug already used for the treatment of this disease called doxorubicin.
If olaratumab is licensed for use in the UK, it could be a new treatment option for patients with advanced soft tissue sarcoma that may improve survival. Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal; Doxorubicin; Humans; Sarcoma Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016000403 Date abstract record published 04/03/2016 |